Spyre Therapeutics Sets Six POC Readouts with SKYLINE Q2 and SKYWAY Q4 Timelines
Spyre Therapeutics prioritizes six proof-of-concept readouts in 2026, with SKYLINE enrollment completing early and Part A now set for Q2, and SKYWAY trials in rheumatoid and psoriatic arthritis on track for Q4. It holds $783 million cash as of Sept 30, 2025, providing runway into H2 2028 and named Kate Tansey Chevlen CCO.
1. Readout Priorities for 2026
Spyre Therapeutics outlined a plan to prioritize six proof-of-concept readouts throughout 2026, aiming to advance its pipeline of antibody therapeutics targeting inflammatory diseases.
2. SKYLINE and SKYWAY Trial Timelines
The SKYLINE ulcerative colitis trial saw SPY001 enrollment complete ahead of schedule, moving Part A data into Q2, while the SKYWAY basket study in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis remains on track for Q4.
3. Financial Runway Through H2 2028
As of September 30, 2025, Spyre holds $783 million in pro forma cash, cash equivalents and marketable securities, securing funding for clinical and operational activities into the second half of 2028.
4. Chief Commercial Officer Appointment
Spyre appointed Kate Tansey Chevlen as Chief Commercial Officer, drawing on her seasoned biopharma commercial leadership to guide market strategy and future product launches.